OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the performance of different camera imaging
systems in assessing the positive predictive values and sensitivity of OTL38 to detect folate
positive ovarian cancer cancers using the gold standard of pathologic review.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania